658 A phase 2 study to assess the safety, efficacy of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer
Paul Rhee(Hanmi Pharmaceutical (South Korea)), Michael Chisamore(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sun Young Rha(Yonsei University), Seung Jae Baek(Seoul National University), Jun‐Eul Hwang(Chonnam National University Hwasun Hospital), Do‐Youn Oh(Seoul National University Hospital), Sang Cheul Oh(Korea University), Jaeyong Cho(Severance Hospital), Keun‐Wook Lee(Seoul National University Bundang Hospital), Dae Young Zang(Second Affiliated Hospital of Dalian Medical University), Taewan Kim(VA North Texas Health Care System), William Ho(Baker Heart and Diabetes Institute), Min Hee Ryu(Asan Medical Center), Byoung Yong Shim(The Catholic University of Korea St. Vincent's Hospital), Eunhye Baek(Hanmi Pharmaceutical (South Korea)), Jeeyun Lee(Samsung Medical Center)
Cited by 2
Related Papers
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Multi-criteria decision making approaches for supplier evaluation and selection: A literature review
|European Journal of Operational Research|2009|2.2k
Supply chain risk management: a literature review
|International Journal of Production Research|2015|1.3k
Integrated analytic hierarchy process and its applications – A literature review
|European Journal of Operational Research|2007|1.2k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k